| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 8049- | IVM, | Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer |
| - | vitro+vivo, | BC, | NA |
| 1070- | IVM, | Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation |
| - | vitro+vivo, | GBM, | NA |
| 7910- | IVT, | Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | H1975 |
| 7893- | IVT, | Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress |
| - | vitro+vivo, | Liver, | NA |
| 8008- | JG, | Juglone, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells |
| - | in-vitro, | NA, | LNCaP |
| 5099- | JG, | Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK |
| - | vitro+vivo, | GBM, | LN229 | - | vitro+vivo, | GBM, | T98G |
| 5117- | JG, | https://pubmed.ncbi.nlm.nih.gov/31283929/ |
| - | vitro+vivo, | Liver, | NA |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1926- | JG, | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
| - | in-vitro, | BC, | MCF7 |
| 1921- | JG, | Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis |
| - | in-vitro, | PC, | NA | - | vitro+vivo, | PC, | NA |
| 8101- | KAE, | Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway |
| - | vitro+vivo, | ESCC, | KYSE150 | - | vitro+vivo, | ESCC, | Eca109 |
| 8066- | KAE, | Rad, | Radiosensitization of non-small cell lung cancer by kaempferol |
| - | in-vivo, | Lung, | A549 |
| 8122- | LA, | ProBio, | Probiotics in colorectal cancer: mechanisms, biomarkers, and adjunct strategies |
| - | Review, | CRC, | NA |
| 863- | Lae, | Amygdalin inhibits the growth of renal cell carcinoma cells in vitro |
| - | in-vitro, | RCC, | NA |
| 8161- | LapC, | Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 | - | in-vitro, | ESCC, | KYSE-510 |
| 8179- | Las, | Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway |
| - | in-vitro, | HCC, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8248- | LCA, | Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H460 |
| 8265- | LE, | Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response |
| - | vitro+vivo, | CRC, | NA |
| - | in-vitro, | BC, | MCF7 |
| 8127- | LF, | Phase I trial of oral talactoferrin alfa in refractory solid tumors |
| - | Trial, | Var, | NA |
| 8188- | LGE, | Citral inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF-7 cells |
| - | in-vitro, | BC, | MCF7 |
| 8186- | LGE, | Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3 |
| - | vitro+vivo, | BC, | NA |
| 8183- | LGE, | Antiproliferative and apoptosis inducing effects of citral via p53 and ROS-induced mitochondrial-mediated apoptosis in human colorectal HCT116 and HT29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 6484- | LIN, | Linalool Inhibits MCF-7 Tumor Growth in a Xenograft Model by Apoptosis Induction and Immune Modulation |
| - | vitro+vivo, | BC, | MCF7 |
| 6481- | LIN, | Linalool inhibits 22Rv1 prostate cancer cell proliferation and induces apoptosis |
| - | in-vivo, | Pca, | 22Rv1 |
| 1025- | LT, | Api, | Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer |
| - | in-vivo, | Lung, | NA |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2918- | LT, | Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS |
| - | in-vitro, | Melanoma, | A375 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | SK-MEL-28 |
| 1317- | LT, | Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2 |
| - | vitro+vivo, | Ovarian, | PA1 |
| 4778- | Lyco, | Lycopene exerts cytotoxic effects by mitochondrial reactive oxygen species–induced apoptosis in glioblastoma multiforme |
| - | in-vitro, | GBM, | GBM8401 |
| 4783- | Lyco, | Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
| 4799- | Lyco, | Anticancer Properties of Lycopene |
| - | Review, | Var, | NA |
| 4796- | Lyco, | The Anti-proliferation Effects of Lycopene on Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 4794- | Lyco, | Anticancer Effect of Lycopene in Gastric Carcinogenesis |
| - | Review, | GC, | NA |
| 2545- | M-Blu, | Reversing the Warburg Effect as a Treatment for Glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | NA, | AD, | NA | - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | T98G |
| 2541- | M-Blu, | Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism |
| - | in-vivo, | Var, | NA |
| 1196- | MAG, | 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression |
| - | in-vitro, | HCC, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4527- | MAG, | Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway |
| - | in-vitro, | ESCC, | TE1 | - | in-vitro, | ESCC, | Eca109 | - | vitro+vivo, | SCC, | KYSE150 |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24/HTB-9 |
| 2500- | meben, | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 995- | MEL, | Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma |
| - | vitro+vivo, | GBM, | NA |
| 1042- | MEL, | Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | LLC1 |
| 2456- | MET, | Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2379- | MET, | Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | BC, | UMUC3 |
| 2384- | MET, | Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vivo, | NA, | NA | - | in-vitro, | Thyroid, | TPC-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:323 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid